Zymeworks secures $250 million in royalty-backed financing from Royalty Pharma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. CART
8. LLY
9. TSLA
10. FICO

Go back to Zymeworks secures $250 million in royalty-backed financing from Royalty Pharma

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

March 2, 2026 6:01 AM EST

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028

VANCOUVER, British Columbia and NEW YORK, March 02,... More